Genelux Corporation
NASDAQ:GNLXBiotechnology
+$0.08 today
- Market cap
- $107.66M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
Volume 0.80M
Average 0.19M
GNLX Total Debt
Short-term and long-term borrowings combined.
Genelux CorporationNASDAQ: GNLX
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 39.6% from a year ago
Total debt stood at $2.5M at the end of Q1 FY2026, up 39.6% from a year earlier and up 48.1% from the prior quarter. Over 3 fiscal years it compounded at -60.0% a year.
Context
- Total debt amounted to 7.7% of total assets at the end of Q1 FY2026, up 3.1 pp from a year earlier.
- Total debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +39.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 1.69M USD
- Year-over-year change
- -9.8%
- 4-year CAGR
- -49.2%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.69M | -9.8% |
| FY2024 | 2024-12-31 | 1.87M | -25.8% |
| FY2023 | 2023-12-31 | 2.52M | -90.4% |
| FY2022 | 2022-12-31 | 26.35M | +4.1% |
| FY2021 | 2021-12-31 | 25.31M | — |
Total Debt vs competitors
How GNLX compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +39.6% is the 2nd highest of 11, against a peer median of -7.4%.
- Total debt amounts to 7.7% of total assets for GNLX, versus a peer median of 3.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $108.6M USD | +18.3% | +16.5% | 37.6% | |
| Mar 2026 | $48.85M USD | -14.4% | -9.0% | 13.9% | |
| Mar 2026 | $15.51M USD | -0.3% | -1.2% | 23.3% | |
| Mar 2026 | $14.34M USD | +16.7% | +38.3% | 13.2% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $7.37M USD | -21.6% | -16.4% | 2.9% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $6.95M USD | +15.9% | +12.1% | 2.7% |
| Mar 2026 | CHF 4.3M CHF | -16.8% | +17.5% | 3.1% | |
GNLXGenelux Corporation | Mar 2026 | $2.5M USD | +39.6% | -60.0% | 7.7% |
| Mar 2026 | $1.8M USD | -83.5% | -56.3% | 0.9% | |
| Mar 2026 | $136K USD | +126.7% | -28.9% | 0.1% | |
| Mar 2026 | $0 USD | -100.0% | -76.4% | 0.0% | |
| Peer median (excluding GNLX) | — | -7.4% | -5.1% | 3.0% | |
Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.5M | 397K | 9.42M | 8.57M | 5.33M |
| Short-term Investments | 0 | 0 | 13.77M | 22.33M | 9.26M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.33M | 1.5M | 1.01M | 653K | 535K |
| Total Current Assets | 5.82M | 1.89M | 24.2M | 31.55M | 15.13M |
| Property, Plant & Equipment (Net) | 2.21M | 1.98M | 3.6M | 3.08M | 3.75M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 92K | 1.66M | 92K | 92K | 144K |
| Total Non-current Assets | 2.3M | 3.64M | 3.69M | 3.17M | 3.9M |
| Total Assets | 8.13M | 5.53M | 27.89M | 34.72M | 19.03M |
| Account Payables | 4.46M | 6.78M | 3.78M | 5.57M | 4.36M |
| Short-term Debt | 6.16M | 16.4M | 653K | 329K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.5M | 170K | 0 | 0 | 0 |
| Other Current Liabilities | 4.11M | 5.16M | 0 | 0 | 0 |
| Total Current Liabilities | 22.48M | 31.63M | 6.55M | 6.9M | 6.23M |
| Long-term Debt | 18.02M | 8.52M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 18.75M | 9.69M | 1.87M | 1.54M | 1.26M |
| Total Liabilities | 41.24M | 41.31M | 8.42M | 8.44M | 7.48M |
| Common Stock | 9K | 9K | 27K | 35K | 38K |
| Retained Earnings | (184.58M) | (189.78M) | (221.52M) | (251.39M) | (283.54M) |
| Accumulated OCI | 2K | 2K | 14K | 64K | 9K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (33.11M) | (35.78M) | 19.47M | 26.27M | 11.54M |
| Total Debt | 25.31M | 26.35M | 2.52M | 1.87M | 1.69M |
| Net Debt | 20.82M | 25.96M | (6.9M) | (6.7M) | (3.65M) |
Genelux Corporation
NASDAQ:GNLX
Intrinsic Alpha fair value
Locked
Current Price
$2.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.